eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Companyâ€™s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
18/06/26	USD 0.000200	0.00%	1,100
17/06/26	USD 0.000200	-66.67%	251

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 01:06:27 19/06/26 am AEST			5-day change	1st Jan Change
0.000200 ^USD	0.00%		-66.67%	-

11/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
08/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI

Market Cap	940 825.79 760.92 712.32 1.33K 89.05K 1.36K 9.14K 3.54K 43.69K 3.53K 3.45K 152K	P/E 2022	-0.78x	P/E 2023	-0.71x
Enterprise Value	2.18M 1.91M 1.76M 1.65M 3.09M 206M 3.14M 21.15M 8.19M 101M 8.17M 7.99M 352M	EV / Sales 2022	3,344,920x	EV / Sales 2023	-
Free-Float	99.75%	Yield 2022 *	-	Yield 2023	-

11/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
08/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI
02/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index	CI
25/06/24	Sector Update: Health Care Stocks Rise in Late Afternoon Trading	MT
25/06/24	Top Midday Decliners	MT
25/06/24	EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives	MT
24/06/24	EFFECTOR Therapeutics, Inc. Announces Cessation of Michael Byrnes, Chief Financial Officer	CI
24/06/24	Effector Therapeutics, Inc. Terminates Its Employees in Connection with the Planned Wind Down of the Company?s Operations	CI
24/06/24	Effector Therapeutics, Inc. Announces Director Resignations	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board	CI
20/05/24	EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	CI
10/05/24	EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

24/08/23	HC Wainwright Starts eFFECTOR Therapeutics With Buy Rating, $5 Price Target	MT
26/05/23	Stifel Upgrades eFFECTOR Therapeutics to Buy From Hold, Adjusts Price Target to $7 From $1.30	MT
10/05/23	Credit Suisse Trims eFFECTOR Therapeutics' Price Target to $5.50 From $7, Keeps Outperform Rating	MT
10/03/23	Credit Suisse Adjusts eFFECTOR Therapeutics' Price Target to $7 From $8, Keeps Outperform Rating	MT
10/01/23	JMP Securities Trims Price Target on eFFECTOR Therapeutics to $1 From $2, Maintains Market Outperform Rating	MT

eFFECTOR Therapeutics, Inc. Stock

Stocks

EFTR

US28202V2079

Biotechnology & Medical Research

Valuation: eFFECTOR Therapeutics, Inc.

Chart: eFFECTOR Therapeutics, Inc.

Latest news : eFFECTOR Therapeutics, Inc.

Analysts' recommendations: eFFECTOR Therapeutics, Inc.

Press Releases: eFFECTOR Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: eFFECTOR Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

13/08/24	FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer	AQ
26/06/24	EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K	PU
24/06/24	EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq	AQ
04/04/24	EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	AQ
06/02/24	EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	AQ

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.02
3 years	0		22.5
5 years	0		1,010.5
10 years	0		1,010.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
13/06/24	Brian Gallagher	Free	Chairman	800	0.0170%
13/06/24	Elizabeth Bhatt	Free	Director	800	0.0170%
13/06/24	Christopher Ehrlich	Free	Director	800	0.0170%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EFFECTOR THERAPEUTICS, INC.	0.00%	-66.67%	-33.33%	-100.00%	940
ARGENX SE	-7.01%	-3.13%	+54.75%	+111.12%	57.55B
WUXI APPTEC CO., LTD.	-0.49%	+8.30%	+62.88%	+67.95%	47.08B
BIONTECH SE	-1.48%	-2.05%	-14.05%	-15.52%	22.92B
INSMED INCORPORATED	+3.45%	+8.13%	+0.52%	+434.66%	22.14B
WUXI BIOLOGICS (CAYMAN) INC.	+4.17%	+8.64%	+27.72%	-15.63%	16.33B
GENMAB A/S	-0.38%	+3.97%	+27.57%	-34.47%	15.97B
EXELIXIS, INC.	+1.68%	+0.03%	+14.73%	+169.55%	12.9B
PHARMAESSENTIA CORPORATION	0.00%	+10.49%	+130.14%	+273.89%	12.85B
MADRIGAL PHARMACEUTICALS, INC.	+1.89%	+4.75%	+83.74%	+122.61%	11.84B
Average	+0.18%	+4.91%	+35.47%	+101.41%	21.96B
Weighted average by Cap.	-1.28%	+6.24%	+43.48%	+114.83%

	2022	2023
Net sales	3.55 3.12 2.88 2.69 5.04 336.57 5.13 34.53 13.37 165.14 13.34 13.05 573.96	-
Net income	-22.66M -19.91M -18.35M -17.18M -32.18M -2.15B -32.72M -220M -85.28M -1.05B -85.08M -83.25M -3.66B	-35.81M -31.46M -28.99M -27.14M -50.84M -3.39B -51.7M -348M -135M -1.66B -134M -132M -5.79B
Net Debt	-6.03M -5.3M -4.88M -4.57M -8.56M -571M -8.7M -58.6M -22.68M -280M -22.63M -22.15M -974M	2.18M 1.91M 1.76M 1.65M 3.09M 206M 3.14M 21.14M 8.18M 101M 8.16M 7.99M 351M